Publication - 2017A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Publication

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo

Simvastatin inhibits interferon-γ signaling by blocking activation of STAT and prevented and reversed disease in our mouse model. We conducted a small, randomized, double-blind, placebo-controlled, phase II clinical trial to test simvastatin as a treatment for vitiligo. Our study does not support the use of oral simvastatin for the treatment of vitiligo. Disparate findings in this study compared with our mouse model may be a result of dosing limitations in human beings because of potential toxicity, which is not a concern in mice.

Full text   

Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE



FAQOther Questions

  • Awareness Days Similar to World Vitiligo Day

    World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...

  • PTSD in Vitiligo?

    Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...